Combining Agents that Target the Tumor Microenvironment Improves the Efficacy of Anticancer Therapy
- 1 January 2008
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 14 (1) , 270-280
Abstract
Purpose: Over the past 60 years, cytotoxic chemotherapy has targeted the cancer cell. Despite this, there have been few cancer cures. A new approach to cancer therapy is to target the multicellular biological entity of the tumor microenvironment.Keywords
This publication has 30 references indexed in Scilit:
- Combination therapy targeting the tumor microenvironment is effective in a model of human ocular melanomaJournal of Translational Medicine, 2007
- Combination angiostatic therapy completely inhibits ocular and tumor angiogenesisProceedings of the National Academy of Sciences, 2007
- Preparing the “Soil”: The Premetastatic NicheCancer Research, 2006
- Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and AngiogenesisJournal of Clinical Oncology, 2005
- The evolution of thalidomide and its IMiD derivatives as anticancer agentsNature Reviews Cancer, 2004
- Tumor Regression by Targeted Gene Delivery to the NeovasculatureScience, 2002
- Endothelial apoptosis in Braf-deficient miceNature Genetics, 1997
- Inhibition of angiogenesis by the antineoplastic agents mitoxantrone and bisantreneBiochemical and Biophysical Research Communications, 1986
- Temporary Remissions in Acute Leukemia in Children Produced by Folic Acid Antagonist, 4-Aminopteroyl-Glutamic Acid (Aminopterin)New England Journal of Medicine, 1948
- THE DISTRIBUTION OF SECONDARY GROWTHS IN CANCER OF THE BREAST.The Lancet, 1889